Status:
UNKNOWN
Norepinephrine vs Norepinephrine and Dobutamine in Cardiogenic Shock
Lead Sponsor:
Central Hospital, Nancy, France
Conditions:
Cardiogenic Shock
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Cardiogenic shock is a frequent cause of admission and death in the intensive care unit. Mortality is about 50%. Once the etiologic treatment has been done, for instance coronary revascularization, m...
Eligibility Criteria
Inclusion
- Patients with cardiogenic shock (ischemic, rythmic, valvular) defined : by cardiac index (CI) \< 2,2 L/min/m² or CI \< 2,5 L/min/m² under vasopressor/inotropic treatment and organ hypoperfusion signs : mottles, capillary refill time , urine output \< 0,5 mL/kg/hour during at least one hour ou renal replacement therapy, consciouness impairment, pulmonary oedema, hyperlactatemia (\> 2 mmoL/L)
- Mean arterial pressure \> 65 mmHg under norepinephrine treatment
- Patients with social coverage
Exclusion
- \< 18 years old
- Pregnancy
- Inclusion in other drug study
- Poisonings with cardiotoxicants
- Patient with intra-aortic ballon pump, extracorporeal life support
- Patient under guardianship
Key Trial Info
Start Date :
January 15 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2020
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT03340779
Start Date
January 15 2018
End Date
May 1 2020
Last Update
November 14 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Nancy-Brabois
Vandœuvre-lès-Nancy, France, 54500